Chemokines and atherosclerosis: focus on the CX3CL1/CX3CR1 pathway

Fractalkine: A Survivor's Guide

(2012) Gemma E. White et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Independent Roles of Monocyte Chemoattractant Protein-1, Regulated on Activation, Normal T-Cell Expressed and Secreted and Fractalkine in the Vulnerability of Coronary Atherosclerotic Plaques

(2012) Jifu Li et al.   CIRCULATION JOURNAL

Association between Serum Neopterin and Inflammatory Activation in Chronic Kidney Disease

(2012) Ashok Kumar Yadav et al.   MEDIATORS OF INFLAMMATION

Fractalkine and Its Receptor (CX3CR1) in Patients with Stable Coronary Artery Disease and Diabetes Mellitus

(2012) Ida Unhammer Njerve et al.   Metabolic Syndrome and Related Disorders

Fractalkine Is Expressed in Early and Advanced Atherosclerotic Lesions and Supports Monocyte Recruitment via CX3CR1

(2012) Moritz Stolla et al.   PLoS One

Fractalkine is an independent predictor of mortality in patients with advanced heart failure

(2012) Lorenz Koller et al.   THROMBOSIS AND HAEMOSTASIS

Erythrocyte Duffy antigen receptor for chemokines (DARC): diagnostic and therapeutic implications in atherosclerotic cardiovascular disease

(2011) Stavros Apostolakis et al.   ACTA PHARMACOLOGICA SINICA

Fractalkine/CX3CR1 and atherosclerosis

(2011) Hong Liu et al.   CLINICA CHIMICA ACTA

Fractalkine Is a Novel Human Adipochemokine Associated With Type 2 Diabetes

(2011) R. Shah et al.   DIABETES

Association of Circulating Fractalkine (CX3CL1) and CX3CR1+CD4+ T Cells with Common Carotid Artery Intima-Media Thickness in Patients with Chronic Kidney Disease

(2011) Ashok Kumar Yadav et al.   Journal of Atherosclerosis and Thrombosis

Therapeutic implications of chemokine-mediated pathways in atherosclerosis: realistic perspectives and utopias

(2010) Stavros Apostolakis et al.   ACTA PHARMACOLOGICA SINICA

Genetic diversity of CX3CR1 gene and coronary artery disease: New insights through a meta-analysis

(2009) Stavros Apostolakis et al.   ATHEROSCLEROSIS

Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediators

(2009) R. B. Schnabel et al.   BLOOD

Aspirin Inhibits Fractalkine Expression in Atherosclerotic Plaques and Reduces Atherosclerosis in ApoE Gene Knockout Mice

(2009) Hong Liu et al.   CARDIOVASCULAR DRUGS AND THERAPY

Interleukin 8 and cardiovascular disease

(2009) S. Apostolakis et al.   CARDIOVASCULAR RESEARCH

Chemokines in Atherosclerosis, Thrombosis, and Vascular Biology

(2008) Christian Weber   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Combined Inhibition of CCL2, CX3CR1, and CCR5 Abrogates Ly6C hi and Ly6C lo Monocytosis and Almost Abolishes Atherosclerosis in Hypercholesterolemic Mice

(2008) Christophe Combadière et al.   CIRCULATION

Chemotaxis, chemokine receptors and human disease

(2008) Tian Jin et al.   CYTOKINE

Interleukin-8 is increased in the membrane of circulating erythrocytes in patients with acute coronary syndrome

(2008) D. N. Tziakas et al.   EUROPEAN HEART JOURNAL

Coronary heart disease epidemics: not all the same

(2008) M Mirzaei et al.   HEART

Fractalkine Deficiency Markedly Reduces Macrophage Accumulation and Atherosclerotic Lesion Formation in CCR2 −/− Mice

(2007) Noah Saederup et al.   CIRCULATION